Procyon Advisors LLC Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Procyon Advisors LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,412 shares of the company’s stock after purchasing an additional 58 shares during the period. Procyon Advisors LLC’s holdings in IDEXX Laboratories were worth $784,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after purchasing an additional 7,441,162 shares during the period. State Street Corp increased its position in IDEXX Laboratories by 2.6% in the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company’s stock valued at $1,894,198,000 after acquiring an additional 97,303 shares during the period. Alliancebernstein L.P. boosted its stake in IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after purchasing an additional 214,529 shares in the last quarter. Geode Capital Management LLC boosted its stake in IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock valued at $971,569,000 after purchasing an additional 26,197 shares in the last quarter. Finally, Blair William & Co. IL boosted its stake in IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after purchasing an additional 7,812 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Stock Up 0.1 %

NASDAQ IDXX traded up $0.63 on Thursday, reaching $540.20. The company had a trading volume of 30,803 shares, compared to its average volume of 423,959. The firm has a market capitalization of $44.89 billion, a price-to-earnings ratio of 53.58, a price-to-earnings-growth ratio of 2.91 and a beta of 1.27. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company’s fifty day moving average is $547.76 and its 200-day moving average is $501.71.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. During the same period in the prior year, the business earned $2.05 EPS. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. Finally, BNP Paribas assumed coverage on IDEXX Laboratories in a report on Thursday, December 7th. They set an “outperform” rating and a $602.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $591.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.